Efficacy and safety of voglibose plus metformin in patients with type 2 diabetes mellitus: A randomized controlled trial

Tae Jung Oh, Jae Myung Yu, Kyung Wan Min, Hyun Shik Son, Moon Kyu Lee, Kun Ho Yoon, Young Duk Song, Joong Yeol Park, In Kyung Jeong, Bong Soo Cha, Yong Seong Kim, Sei Hyun Baik, In Joo Kim, Doo Man Kim, Sung Rae Kim, Kwan Woo Lee, Jeong Hyung Park, In Kyu Lee, Tae Sun Park, Sung Hee ChoiSung Woo Park

    Research output: Contribution to journalArticlepeer-review

    12 Citations (Scopus)


    Background: Combination of metformin to reduce the fasting plasma glucose level and an α-glucosidase inhibitor to decrease the postprandial glucose level is expected to generate a complementary effect. We compared the efficacy and safety of a fixed-dose combination of voglibose plus metformin (vogmet) with metformin monotherapy in drug-naïve newly-diagnosed type 2 diabetes mellitus. Methods: A total of 187 eligible patients aged 20 to 70 years, with a glycosylated hemoglobin (HbA1c) level of 7.0% to 11.0%, were randomized into either vogmet or metformin treatments for 24 weeks. A change in the HbA1c level from baseline was measured at week 24. Results: The reduction in the levels of HbA1c was −1.62%±0.07% in the vogmet group and −1.31%±0.07% in the metformin group (P=0.003), and significantly more vogmet-treated patients achieved the target HbA1c levels of <6.5% (P=0.002) or <7% (P=0.039). Glycemic variability was also significantly improved with vogmet treatment, estimated by M-values (P=0.004). Gastrointestinal adverse events and hypoglycemia (%) were numerically lower in the vogmet-treated group. Moreover, a significant weight loss was observed with vogmet treatment compared with metformin (−1.63 kg vs. −0.86 kg, P=0.039). Conclusion: Vogmet is a safe antihyperglycemic agent that controls blood glucose level effectively, yields weight loss, and is superior to metformin in terms of various key glycemic parameters without increasing the risk of hypoglycemia.

    Original languageEnglish
    Pages (from-to)276-286
    Number of pages11
    JournalDiabetes and Metabolism Journal
    Issue number3
    Publication statusPublished - 2019 Jun 1

    Bibliographical note

    Funding Information:
    This study was designed and led by vogmet study group and funded by CJ Healthcare Co.

    Publisher Copyright:
    Copyright © 2019 Korean Diabetes Association


    • Diabetes mellitus
    • Metformin
    • Type 2
    • Voglibose

    ASJC Scopus subject areas

    • Endocrinology, Diabetes and Metabolism


    Dive into the research topics of 'Efficacy and safety of voglibose plus metformin in patients with type 2 diabetes mellitus: A randomized controlled trial'. Together they form a unique fingerprint.

    Cite this